Racura to Present CPACS Data at GCOS 2026
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Racura to Present CPACS Phase 1
RC220 and Doxorubicin Data at the
2026 Global Cardio-Oncology Summit
§ Poster presentation accepted for the Global Cardio-Oncology Summit 2026 for the abstract, “Car-
dioprotection & Anticancer Synergy (CPACS) – A Phase 1 Study of RC220 in Combination with Doxo-
rubicin – Trial in Progress”
§ Presentation will provide an update on the ongoing CPACS Phase 1 trial of RC220 with doxorubi-
cin in patients with advanced solid tumours
9 July 2026
Racura Oncology Limited (“Racura” or the “Company”) is pleased to announce that it has been accepted
to present at the Global Cardio-Oncology Summit 2026, to be held in Williamsburg (Virginia, USA) from 5
to 7 October 2026. The poster presentation will provide a clinical update on Racura’s ongoing
Cardioprotection & Anticancer Synergy (CPACS) Phase 1 study of RC220 in combination with doxorubicin
in patients with advanced solid tumours.
Racura Oncology CEO and Managing Director, Dr Daniel Tillett, commented: “Acceptance of our CPACS
clinical study for presentation at the 2026 Global Cardio-Oncology Summit highlights the growing interest in
RC220’s potential to address cardiotoxicity, one of the key limitations of anthracycline-based cancer
therapy. The study is evaluating if RC220 can be safely combined with doxorubicin to enhance anticancer
activity and reduce cardiac injury. We look forward to updating the international cardio-oncology community
on the progress of this important trial.”
A copy of the accepted abstract is attached to this release.
Significance of Anthracycline Cardiotoxicity
Anthracyclines remain central to many anticancer treatment regimens, but their clinical use is limited by
irreversible cardiotoxicity. RC220 is a proprietary formulation developed by Racura of (E,E)-bisantrene, a
clinically validated small molecule anticancer agent recently shown to act through G-quadruplex DNA and
RNA binding, leading to potent silencing of c-MYC oncogene expression in preclinical cancer models.
RC220 in combination with doxorubicin has shown improved anticancer activity in human and murine
tumour models and reduced anthracycline cardiotoxicity in human cardiomyocytes and multiple animal
cardiac models.
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
CPACS Trial
The CPACS study is a multicentre, open-label, two-part Phase 1 trial in adult patients with advanced solid
tumours, with enrolment ongoing in Australia, Hong Kong and will soon commence in South Korea. Part 1
is a Bayesian Optimal Interval (BOIN)-guided dose-escalation study of IV RC220 administered in
combination with 60 mg/m² doxorubicin, preceded by monotherapy safety lead-in cycles of each agent.
The primary objective is to assess the safety and tolerability of the combination, with secondary objectives
including maximum tolerated combined dose, pharmacokinetics, anti-tumour efficacy and exploratory
cardioprotection biomarkers.
Following interim review, Part 2 will further evaluate safety, tolerability, preliminary anticancer activity and
protection of cardiac function after anthracycline exposure.
– ENDS –
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 3
Cardioprotection & Anticancer Synergy (CPACS) – A Phase 1
Study of RC220 in Combination with Doxorubicin – Trial in
Progress
Feroz Ahmad1
, Michelle Huh1
, Corli Merry1
, Mahmood Alam2
, Roland Ching Yu Leung3
, Daniel Tillett1
and Marinella Messina1
1
Racura Oncology, Sydney, Australia, 2
Cancer Care Foundation, Australia, 3
Queen Mary Hospital, Hong Kong.
Background
Anthracyclines remain an essential part of many anticancer protocols, but their clinical use is limited by
irreversible cardiotoxicity. RC220 is a new formulation of (E,E)-bisantrene, a clinically proven small molecule
anticancer agent that has recently been discovered to function via G-quadruplex DNA and RNA binding, resulting
in silencing of c-MYC oncogene expression.
Preclinical studies of RC220 combined with doxorubicin have shown improved anticancer activity in murine
tumor models, while also demonstrating reduced anthracycline cardiotoxicity in human cardiomyocytes, and
murine and canine cardiac models.
Methods
This is a multicenter open-label, 2-part Phase 1 study in adult patients with advanced solid tumors recruiting
patients in Australia, Hong Kong and South Korea.
Part 1 is a BOIN guided dose escalation study of IV RC220 administered in combination with 60 mg/m²
doxorubicin, preceded by monotherapy cycles of each agent. The primary objective is the safety and tolerability
of the combination, with secondary objectives to define the maximum tolerated combined dose (MTCD), PK,
anti-tumor efficacy, and exploratory cardioprotection biomarkers.
Following an interim review, a Part 2 dose-expansion cohort will further assess safety, tolerability, preliminary
anticancer activity, and protection of cardiac function (including GLS, cMRI, LVEF, CTRCD, cardiac biomarkers
and VO2peak) after anthracycline exposure in patients with solid tumors.
Results to date
The first cohort of three patients treated with RC220 at 40 mg/m² and doxorubicin at 60 mg/m2
has been
reviewed by the independent Safety Review Committee (SRC). The combination in up to five cycles was found
to have an acceptable safety profile with no dose-limiting toxicity (DLT) or other significant safety concerns.
Importantly, in preclinical studies, 40 mg/m2
of RC220 was protective against doxorubicin-induced
cardiotoxicity. The SRC has allowed escalation to the next RC220 dose level of 80 mg/m².
Conclusions
Initial safety findings at the starting dose level support continued dose escalation of RC220 in combination with
doxorubicin, and enrolment is ongoing.
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 4
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to
silence cancer.
Racura’s lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily acts through G4-
DNA and RNA binding, resulting in potent silencing of MYC, an important regulator of cancer growth. (E,E)-
bisantrene has demonstrated therapeutic activity in cancer patients and has a well-characterised safety
profile. Recent Racura discoveries have enabled composition of matter IP filings that may provide 20 years
of patent protection over (E,E)-bisantrene.
Racura is advancing RC220, a proprietary formulation of (E,E)-bisantrene, to address significant unmet
needs across multiple oncology indications. Its clinical programs include a Phase 3 program in acute
myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small
cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program combining RC220 with doxorubicin, where
Racura aims to deliver both cardioprotection and enhanced anticancer activity for patients with solid
tumours.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of
Health, UNC School of Medicine, the University of Wollongong and the University of Newcastle. Racura is
actively exploring partnerships, licence agreements and commercial merger and acquisition opportunities
to accelerate global access to RC220 for patients with cancer. Learn more at www.racuraoncology.com.
For questions about this announcement or previous Racura Oncology announcements, please visit our
Interactive Announcements page.
Racura encourages investors to go paperless by registering their details with the Company’s share registry,
Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Share your feedback
Discover